Understanding Pneumococcal Carriage and Disease 2017/2018

The Oxford Vaccine Group is currently inviting healthy children aged 13 – 48 months to take part in a swabbing study looking at how much pneumococcal bacteria is carried in the nose.

Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals at some time in their lives and can sometimes go on to cause severe infections such as meningitis and pneumonia. There are over 100 types of pneumococcus and children in the UK have been routinely immunised against pneumococcal disease since 2006.

Persistence of the immune response after immunisation with Ebola virus vaccines (PRISM Study)

The Oxford Vaccine Group are inviting participants of the ‘Evaluating Vaccines against Ebola’ vaccine study to take part in a study looking at the persistence of immunity induced by the vaccines administered in that study  (Ad26.ZEBOV and MVA-BN-Filo).

This study would involve a single clinic visit at which you would have a blood test and any relevant medical information would be collected.

This study will help us collect new information on how well these vaccines might be able to provide long term protection against Ebola Virus disease.

Investigating Typhoid Fever Pathogenesis (TYGER)

You are invited to take part in a study to investigate typhoid fever and how the typhoid bacteria causes disease.  The study is being run by the Oxford Vaccine Group which is part of the University of Oxford.

If you are aged 18 to 60 years old and are, in good health, then you may be eligible to take part in the study. We will provide reimbursement for your time, inconvenience and travel. The total study participation time is 12 months.

Background

ImmunoglobuliN in the Treatment of Encephalitis

The IgNiTE Study

A study testing a new treatment for children with encephalitis.

The Department of Paediatrics at the University of Oxford, in collaboration with NHS Trusts across the United Kingdom, is currently running a study for hospitalised children with encephalitis. The study will assess whether a treatment called intravenous immunoglobulin (IVIg, sometimes referred to as antibody treatment) has any benefit for these children when given early during the hospital admission.

Subscribe to Trials - Oxford Vaccine Group RSS